Spine BioPharma
New York, US · Founded 2015 · Delaware corporation · 8 employees on LinkedIn · 3 known investors
Find your way into Spine BioPharma
282 people in our graph share verified history with the Spine BioPharma team — schools, employers, funds. One of them is your warm intro.
Teresa Chanunlockedknows Jason Gallagher · together at Johnson & Johnson (overlapped)
×6knows the team · via Johnson & Johnson
×2knows the team · via Novo Nordisk
×2knows the team · via Seton Hall University
knows the team · via Paradigm Spine LLC
Developing non-surgical, non-opioid therapies for degenerative disc disease through targeted peptide injection.
Founders & leadership
Spine BioPharma was founded in 2015 by Marc R. Viscogliosi.
MR
Marc R. ViscogliosiinFounder · Chairman & CEOMarc Viscogliosi is a medical device executive with over two decades of experience in company operations, capital raises, and regulatory strategy. He holds multiple issued medical device patents and has led products through FDA approvals and payer coverage processes.
FM
Fran MageeinChief Technology Officerformer
JG
Jason GallagherinCCO & COO; Head of Strategy & Commercialization2023–2025Jason Gallagher is Chief Commercial Officer and Chief Operations Officer at Spine BioPharma, which develops non-surgical, non-opioid therapies for degenerative disc disease. He has over 20 years of experience in biopharma across startups, specialty therapeutics, rare disease, regenerative medicine, and large-cap pharmaceutical companies.
Board
JJ
John J. ViscogliosiBoard director
TB
Thomas Bumol, PhDBoard director
FC
Frank Cammisa, MDBoard director
Investors · 3
Also in the syndicate · 2
Pacira Biosciences, Inc.Viscogliosi Bros., LLC
Reported raises · per SEC filings
Form D private placements$52.2M disclosed across 8 rounds · 2021–2026
▶$384.8KraisedJun 2026 · 3 investors · PharmaceuticalsRule 506(b)
▶$384.8KraisedJun 2026 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Fran MageeExecutive Officer
- John J. ViscogliosiDirector
- Thomas Bumol, PhDDirector
- Marc R. ViscogliosiExecutive Officer, Director
- Frank Cammisa, MDDirector
- Offering amount
- $8.5M
- Amount sold
- $384.8K
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.5MraisedDec 2024 · 10 investors · PharmaceuticalsRule 506(b)
▶$13.5MraisedDec 2024 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas Bumol, PhDDirector
- Fran MageeExecutive Officer
- Jason GallagherExecutive Officer
- Marc R. ViscogliosiExecutive Officer, Director
- Frank Cammisa, MDDirector
- John J. ViscogliosiDirector
- Offering amount
- $23.5M
- Amount sold
- $13.5M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.4MraisedOct 2023 · 3 investors · PharmaceuticalsRule 506(b)
▶$2.4MraisedOct 2023 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frank Cammisa, MDDirector
- Marc R. ViscogliosiExecutive Officer, Director
- Fran MageeExecutive Officer
- John J. ViscogliosiDirector
- Thomas Bumol, PhDDirector
- Offering amount
- $15M
- Amount sold
- $2.4M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.9MraisedAug 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.9MraisedAug 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Frank Cammisa, MDDirector
- Fran MageeExecutive Officer
- John J. ViscogliosiDirector
- Thomas Bumol, PhDDirector
- Marc R. ViscogliosiExecutive Officer, Director
- Offering amount
- $13M
- Amount sold
- $1.9M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13MraisedFeb 2023 · 8 investors · PharmaceuticalsRule 506(b)
▶$13MraisedFeb 2023 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas Bumol, PhDDirector
- John J. ViscogliosiDirector
- Frank Cammisa, MDDirector
- Marc R. ViscogliosiExecutive Officer, Director
- Fran MageeExecutive Officer
- Offering amount
- $13M
- Amount sold
- $13M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13MraisedMar 2022 · 6 investors · PharmaceuticalsRule 506(b)
▶$13MraisedMar 2022 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Thomas Bumol, PhDDirector
- John J. ViscogliosiDirector
- Fran MageeExecutive Officer
- Marc R. ViscogliosiExecutive Officer, Director
- Frank Cammisa, MDDirector
- Offering amount
- $30.4M
- Amount sold
- $13M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedApr 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$3MraisedApr 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- LLC Viscogliosi Brothers,Executive Officer
- Marc R. ViscogliosiExecutive Officer
- John J ViscogliosiExecutive Officer
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Apr 2021
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5MraisedMar 2021 · 14 investors · PharmaceuticalsRule 506(b)
▶$5MraisedMar 2021 · 14 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- LLC Viscogliosi Brothers,Executive Officer
- John J ViscogliosiExecutive Officer
- Marc R. ViscogliosiExecutive Officer
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $25K
- First sale
- Mar 2021
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Spine BioPharma’s TGF-β Antagonist Misses Primary Endpoint in Phase III Degenerative Disc Disease Trial | PharmExecpharmexec.com · Aug 2026Frequently asked questions
- What does Spine BioPharma do?
- Developing non-surgical, non-opioid therapies for degenerative disc disease through targeted peptide injection.
- Who founded Spine BioPharma?
- Spine BioPharma was founded by Marc R. Viscogliosi in 2015.
- Who are Spine BioPharma's investors?
- Spine BioPharma's investors include Blindspot Ventures Management Co.
- How much funding has Spine BioPharma raised?
- Spine BioPharma has disclosed $52.2M raised across 8 rounds.
- Where is Spine BioPharma headquartered?
- Spine BioPharma is headquartered in New York, US.